Patients with Mantle Cell Lymphoma: We Need Your Help!
Lymphoma Canada is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR) for an upcoming drug review on:
Brexucaptagene Autoleucel (KTE-X19), a CAR-T cell therapy, for relapsed or refractory Mantle Cell Lymphoma (MCL)
If you have MCL and have received this treatment, you can help by completing our survey. You can still participate in this survey if you have not received this therapy. You do not need to have relapsed or refractory MCL to participate.
The survey provides us with the patient input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Monday, January 11, and should only take between 15-20 minutes of your time.
You may access the survey by clicking the button below:
